Andrés Felipe Escobar González: Developing Anticoagulants That Prevent Thrombosis While Preserving Hemostasis
Andrés Felipe Escobar González, Pediatric Hematologist, Hemophilia Program at Medicarte, shared a post on LinkedIn about a recent article by Surasak Wichaiyo, published in JTH, adding:
“Received: 7 May 2026 – Revised: 9 July 2026 – Accepted: 3 August 2026
Educational Review
Pharmacology of anticoagulants: from heparin to novel target – specific agents
Surasak Wichaiyo
Anticoagulation therapy has undergone a remarkable evolution, from traditional agents such as heparin and vitamin K antagonists to direct oral anticoagulants and emerging therapies targeting specific coagulation factors.
In this review, ‘Pharmacology of Anticoagulants: From Heparin to Novel Target-Specific Agents,’ Surasak Wichaiyo explores the pharmacological mechanisms, clinical applications, and future perspectives of anticoagulant therapy, highlighting the growing interest in factor XI and XII inhibition.
One of the most exciting challenges in modern thrombosis research is developing anticoagulants that effectively prevent pathological thrombus formation while preserving physiological hemostasis and minimizing bleeding complications.
This evolving therapeutic landscape may open new opportunities for patients at high risk of both thrombosis and bleeding.”
Title: Pharmacology of anticoagulants: from heparin to novel target-specific agents
Authors: Surasak Wichaiyo
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery